NCT06091930View on ClinicalTrials.gov

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

June 9, 2028

Study Completion Date

September 10, 2028

Conditions
Gastrointestinal CancerLung CancerPancreatic CancerColorectal CancerHead and Neck CancerLiver Cancer
Interventions
DRUG

BI 765049

BI 765049

DRUG

Ezabenlimab

Ezabenlimab

Trial Locations (9)

10048

NOT_YET_RECRUITING

National Taiwan University Hospital, Taipei

11217

NOT_YET_RECRUITING

Taipei Veterans General Hospital, Taipei

200120

NOT_YET_RECRUITING

Shanghai East Hospital, Shanghai

277-8577

RECRUITING

National Cancer Center Hospital East, Chiba, Kashiwa

573-1191

NOT_YET_RECRUITING

Kansai Medical University Hospital, Osaka, Hirakata

104-0045

RECRUITING

National Cancer Center Hospital, Tokyo, Chuo-ku

135-8550

RECRUITING

Japanese Foundation for Cancer Research, Tokyo, Koto-ku

03722

NOT_YET_RECRUITING

Severance Hospital, Seoul

06351

NOT_YET_RECRUITING

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY